Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
June 28 2023 - 3:05PM
Phaxiam Therapeutics announces its new mnemonic code on Euronext
and Nasdaq: PHXM
Phaxiam
Therapeutics announces its new mnemonic code on Euronext
and Nasdaq: PHXM
Lyon (France) and Cambridge (MA, US),
June 28, 2023 - Phaxiam Therapeutics (Nasdaq & Euronext:
FR0011471135), announces change of the mnemonic code of its
share from ERYP to PHXM,
following the merger between ERYTECH and PHERECYDES. The change has
been notified by Euronext and will be effective from June 29,
2023.
- Company name: Phaxiam
Therapeutics
- ISIN code: FR0011471135
- Mnemonic:
PHXM
- Listing: Euronext Paris
(Compartment C) and Nasdaq
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company
developing innovative treatments for resistant bacterial
infections, which are responsible for many serious infections. The
company is building on an innovative approach based on the use of
phages, natural bacterial-killing viruses. PHAXIAM is developing a
portfolio of phages targeting 3 of the most resistant and dangerous
bacteria, which together account for more than two-thirds of
resistant hospital-acquired infections: Staphylococcus aureus,
Escherichia coli and Pseudomonas aeruginosa.
PPHAXIAM is listed on the Nasdaq Capital Market
in the United States (ticker: PHXM) and on the Euronext regulated
market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is
part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid &
Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech
indexes.
For more information, please visit www.erytech.com
Contacts
PHAXIAMEric SoyerCOO & CFO+33
4 78 74 44 38 investors@erytech.com |
NewCapMathilde Bohin / Louis-Victor
Delouvrier Relations investisseursArthur
RouilléRelations Médias +33 1 44 71 94 94
phaxiam@newcap.eu |
- PR_PHAXIAM_Mnémo_062823_EN
Phaxiam Therapeutics (LSE:0QSS)
Historical Stock Chart
From Apr 2024 to May 2024
Phaxiam Therapeutics (LSE:0QSS)
Historical Stock Chart
From May 2023 to May 2024